Mogo to Announce Q1 2025 Financial Results May 8, 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)--Mogo Inc. (TSX:MOGO) (NASDAQ:MOGO) ('Mogo' or the 'Company'), a digital wealth and payments business, today announced it will hold a conference call and webcast to discuss its Q1 2025 financial results on Thursday, May 8, 2025 at 3:00 p.m. ET. The call will be hosted by David Feller, Mogo's Founder & CEO, and Greg Feller, President & CFO. The live webcast will include a slide presentation. The Company will issue its financial results prior to market open on May 8.
CONFERENCE CALL DETAILS:
About Mogo
Mogo Inc. (NASDAQ:MOGO; TSX:MOGO) is a financial technology company with three distinct business lines: wealth, lending, and payments. Our mission is to provide consumers with innovative financial solutions that drive long-term financial health and success. We operate with a differentiated approach in each business, leveraging technology, behavioral science, and financial tools to create unique value propositions in our respective markets.
Our wealth and lending businesses are focused on the Canadian market, where we are the only subprime consumer lender that also offers a holistic wealth and investing solution. This unique integration is designed to help consumers transition from borrowing and debt to long-term wealth building. Separately, our payments business is operated through Carta Worldwide, a wholly owned subsidiary that provides modern card issuing and processing solutions, primarily in Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per share, resulting in gross proceeds of approximately $2.67 million, before deducting offering fees and other expenses payable by the Company. In consideration for the exercise of the Existing Warrants for cash, the investors received 6,223,609 G-1 warrants (the "G-1 Warrants") and 2,667,261 G-2 warrants (the "G-2 Warrants) to purchase up to an aggregate of 8,890,870 shares of common stock (the "New Warrants"). The G-1 Warrants are exercisable immediately at an exercise price of $0.425 per common share and will expire five years from the issuance date. The G-2 Warrants are exercisable upon shareholder approval at an exercise price of $0.425 per common share and will expire five years from the issuance date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective resale registration statements on Form S-1 (File Nos. 333-267412 and 333-273015). The transaction is expected to close no later than June 20, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes. The New Warrants are being issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such New Warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the New Warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillinresistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and completion of the offering; the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & Chief Executive Officer Tel: 917-533-1469 Email: davidluci@ View original content: SOURCE Acurx Pharmaceuticals, Inc. Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Best Stock to Buy Right Now: Shopify vs Lightspeed?
Written by Brian Paradza, CFA at The Motley Fool Canada Canadian tech investors hunting for growth in June may find themselves weighing two prominent TSX stocks: the e-commerce giant Shopify (TSX:SHOP) and the beaten-down retail software specialist Lightspeed Commerce (TSX:LSPD). Both had their struggles, one has recovered substantially, and they offer distinct paths to potential returns. However, their risk profiles and current trajectories couldn't be more different. Let's break down which growth stock might be the better fit for your portfolio today. Shopify isn't just an online store builder anymore; it has evolved into a global commerce operating system. Its latest quarterly results (Q1 2025) reinforced its strength: revenue surged 27% year-over-year to US$2.4 billion, gross merchandise volume (GMV) grew 23%, and its free cash flow margin hit a healthy 15%. Crucially, its Payments platform now operates in 39 countries after a massive expansion, achieving 64% penetration of its GMV. Shopify's key advantage is its proven resilience and profitability. It generates significant, self-sustaining cash flow. Operating margins expanded to 14.8% over the past 12 months, up dramatically from 3.7% in 2023. Management emphasizes agility – reacting swiftly to challenges like new tariffs by rolling out features like localized buying filters and artificial intelligence (AI) powered duty calculators (' in days or weeks. This execution speed, combined with a diverse merchant base spanning tiny startups to well-established retail giants, provides stability. However, quality comes at a price. Shopify stock trades at a forward price-to-earnings (P/E) ratio near 75 and a forward enterprise-value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) multiple of 67.3. You are paying handsomely for this premium growth and stability. While Shopify's growth rate is impressive (targeting mid-20% revenue growth for the second quarter), the large-cap stock's growth rate is naturally slowing from its hyper-growth past. Trade conflicts and economic slowdowns remain potential headwinds. Lightspeed presents a stark contrast. Once a high-flyer, its stock sits at a painful 90% below its all-time highs. Investor sentiment remains low following past missteps and a major restructuring. Yet, here lies the potential opportunity. The company is showing signs of a possible turnaround. Revenue growth, while slower than Shopify's, remains respectable at around 18% recently. Management is aggressively repurchasing shares, buying back over 12% of the outstanding stock in the past year at depressed prices – a strong signal it believes the stock is undervalued. Gross margins are expanding due to tighter cost controls and existing customers adopting more modules (increasing average revenue per user). Crucially, Lightspeed is inching towards free-cash-flow break-even and sustained profitability within the next one to two years. Valuation is Lightspeed Commerce stock's compelling argument. Its forward P/E sits at a much cheaper 19.7, and its forward EV/EBITDA is 14.1 – far below Shopify's multiples. If Lightspeed successfully executes its restructuring, demonstrates clear sustainable profits, and rebuilds investor confidence, the stock could see a dramatic re-rating upwards. Triple-digit percentage gains aren't out of the question for patient investors if everything clicks. The catch? Significant execution risk remains. The market is still in 'wait-and-see' mode. Lightspeed needs to consistently hit its targets, prove its restaurant and retail segments are solidly growing post-restructuring, and overcome the stigma attached to its name. It currently lacks Shopify's current cash flow safety net. So, which is the better TSX tech stock to buy now? The answer hinges entirely on one's risk tolerance and investment horizon. Choose Shopify stock if you prioritize stability, proven profitability, strong cash flow, and market leadership, and you're comfortable paying a premium valuation for a company with a clear path to solid and profitable growth. Shopify is the 'sleep-easy' growth stock for the long haul. Otherwise, consider Lightspeed Commerce stock if you have a higher risk tolerance and seek deep value with explosive upside potential, and you believe management can deliver on profitability promises, reignite growth, and win back the market's favour. Looking ahead, Shopify stock may offer a smoother ride on a well-paved highway. Lightspeed offers a potentially thrilling, but much bumpier, path through uncharted territory. For most investors seeking reliable growth in the Canadian tech sector today, Shopify's combination of execution, profitability, and resilience makes it the stronger, albeit pricier, choice. Lightspeed is a fascinating speculative bet for those willing to embrace its higher risk in hopes of a spectacular rebound. Carefully weigh where you fall on that spectrum before hitting the buy button. The post Best Stock to Buy Right Now: Shopify vs Lightspeed? appeared first on The Motley Fool Canada. More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Shopify. The Motley Fool recommends Lightspeed Commerce. The Motley Fool has a disclosure policy. 2025
Business Wire
an hour ago
- Business Wire
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Production Capacity by 15%
TOKYO--(BUSINESS WIRE)--Dai Nippon Printing Co., Ltd. (DNP) is pleased to announce the September operational launch of a coating device compatible with 2,500 mm-width high functional optical film at our Mihara Plant in Hiroshima Prefecture. The operational launch of the second wide coating device comes in response to market and consumer needs, and will boost production capacity by more than 15% on an area basis. With the increased capacity, DNP will accommodate the demand for high functional optical film for 65-inch large-screen TVs, with horizontal and vertical dimensions of 1,436.4 mm x 809.0 mm, which are expected to increase at a compound annual growth rate (CAGR) of approximately 6% between 2025 and 2030 1 on an area basis. [Features] Facilitates the efficient manufacture, or imposition, of high function optical film for 65 inch large screen displays. Designed to facilitate in-line multi-layer coating, for the needs of high-end TV models, which enable to reduce reflected light and improve visibility compared to single-layer products. By introducing new technologies that reduce power consumption and innovating production processes, the introduction of the new line is expected to reduce annual CO₂ emissions by approximately 30% compared to devices in current use. [Looking Ahead] DNP will expand its supply of high functional optical film to polarizer manufacturers in China, along with other countries and regions, aiming for annual sales of approximately 110 billion yen in FY 2026. 1: Source: Display Long-Term Demand Forecast Tracker – 1Q25, Omdia. More Details About DNP DNP was established in 1876, and has become a leading global company that leverages print-based solutions to engineer fresh business opportunities while protecting the environment and creating a more vibrant world for all. We capitalize on core competencies in microfabrication and precision coating technology to provide products for the display, electronic device, and optical film markets. We have also developed new products, such as vapor chamber and reflect array that offer next-generation communication solutions for more people-friendly information society.
